Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for at least 5 years~* Candidate for islet cell transplantation based upon local accepted practice and guidelines~* Reduced awareness of hypoglycaemia~Exclusion Criteria:~* Treatment with any anti-diabetic medication other than insulin including insulin pump within 4 weeks of trial start~* Any previous organ transplantation~* A history of acute idiopathic or chronic pancreatitis~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Liraglutide placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).